血清蛋白质组学在胰腺癌诊断中的进展  

Research progress of serum proteomics technology in biomarkers of pancreatic cancer

作　　者：马小磊[1] 陈炯[1] 

机构地区：[1]安徽医科大学附属省立医院普外科,合肥230001

出　　处：《国际外科学杂志》2014年第3期201-204,共4页International Journal of Surgery

基　　金：安徽省科技攻关计划项目（No.11010402172）;安徽省国际科技技术合作计划项目（No.1008070038）

摘　　要：胰腺癌是一种恶性程度很高的消化道肿瘤,近年来胰腺癌发病率有明显升高的趋势.由于胰腺癌早期确诊率不高,其手术切除率很低,预后极差.因此,提高胰腺癌的早期诊断率对于改善本病的预后有着很重要的意义.胰腺癌的早期诊断在很大程度上依赖肿瘤标志物的检测,近年来蛋白质组学技术发展迅速,广泛应用于临床研究,为肿瘤标志物的寻找提供了一条有效的途径.在所有的标本中,血清因其容易取得,允许重复检测等特点,成为最理想的生物学标本.本文就蛋白质组学技术在胰腺癌患者血清检测中的作用进行综述.Pancreatic cancer is a kind of high degree of malignant gastrointestinal tumor, and its incidence has increased significantly in recent years. Due to the low early diagnosis rate, and the extreme low middile or late re- section rate of pancreatic cancer, Pancreatic cancer＇s prognosis is poor. Therefore, improving the early diagnostic rate of pancreatic cancer has very important significance for improving the prognosis. Early diagnosis of pancreatic cancer is dependent on tumor markers detection to a great extent. And proteomics progress rapidly in recent years and has been widely applied in clinical research. It provides an effective way to find markers. Among all of the spec- imens, secrum is easy to obtain, and it allows repetitive detection. What is more, secmm is also renewable. So it is the most ideal for biological specimens. In this review, the proteomies technology role in pancreatic cancer patients serum detection were summarized.

关 键 词：蛋白质组学 胰腺肿瘤 诊断 血清 肿瘤标志物 

分 类 号：R735.9[医药卫生—肿瘤]